6/17/2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing confidence in the company’s mitapivat drug ahead of trial results. The financial services firm believes that the drug will show considerable reductions in vaso-occlusive crises […]

Source: Yahoo

6/15/2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement […]

Source: Yahoo

6/11/2025

Agios Pharmaceuticals is down some 40% since I last looked at this commercial stage biotech. Read the report to find updates on my thesis on the AGIO stock.

Source: SeekingAlpha

6/9/2025

Presenter SpeechSalveen Richter Great good morning, everyone, and thank you so much for joining us. We're really pleased to kick off the Goldman Sachs Healthcare Conference with the Agios team. So...

Source: Finnhub

6/5/2025

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

6/4/2025

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

5/28/2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presen

Source: Yahoo

5/14/2025

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. “The clinical results and scientific insights being

Source: Yahoo

5/9/2025

We didn't see Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) stock surge when it reported robust earnings recently. We...

Source: Yahoo

5/9/2025

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A re

Source: Yahoo

5/2/2025

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

Source: Yahoo

5/2/2025

CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A

Source: Yahoo

5/2/2025

Agios Pharmaceuticals Inc (AGIO) reports a 6% revenue increase and outlines promising pipeline developments, despite facing revenue and expense challenges.

Source: Yahoo

5/2/2025

The following slide deck was published by Agios Pharmaceuticals, Inc.

Source: SeekingAlpha

5/1/2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsChris Taylor – Vice President-Investor...

Source: SeekingAlpha

5/1/2025

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 13.89% and 11.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/1/2025

CAMBRIDGE, Mass. AP) — Agios Pharmaceuticals Inc. AGIO) on Thursday reported a loss of $89.3 million in its first quarter.

Source: Yahoo

5/1/2025

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable

Source: Yahoo

5/1/2025

Q1 2025 Financial Results and Business Update 1 May 1, 2025 ...

Source: Finnhub

4/25/2025

88 Sidney Street, Cambridge, Massachusetts 02139 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, JUNE 18, 2025 Dear...

Source: Finnhub